The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesPeptide ELISA: Antibody detection limit dilution 1/128000.
WB: Use at a concentration of 0.1 - 0.3 µg/ml. Detects a band of approximately 58 kDa (predicted molecular weight: 58 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionCatalyzes the formation of aromatic C18 estrogens from C19 androgens.
Tissue specificityBrain, placenta and gonads.
Involvement in diseaseDefects in CYP19A1 are a cause of aromatase excess syndrome (AEXS) [MIM:139300]; also known as familial gynecomastia. AEXS is characterized by an estrogen excess due to an increased aromatase activity. Defects in CYP19A1 are the cause of aromatase deficiency (AROD) [MIM:107910]. AROD is a rare disease in which fetal androgens are not converted into estrogens due to placental aromatase deficiency. Thus, pregnant women exhibit a hirsutism, which spontaneously resolves after post-partum. At birth, female babies present with pseudohermaphroditism due to virilization of extern genital organs. In adult females, manifestations include delay of puberty, breast hypoplasia and primary amenorrhoea with multicystic ovaries.
Sequence similaritiesBelongs to the cytochrome P450 family.